Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here  to learn how we are responding.

Congress Materials

Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Reilly B, Shaik N, Lin S April 10, 2021 AACR 2021 Hematology

Virtual healthy control matching for renal impairment studies: a case study with glasdegib

View Presentation
Poster Discussion
Maze D, Walter RB, Merino Vega D, Bell T, O’Hara L,   Peloquin F, Morgan L, Hernandez-Aldama L, Healy J,   Panter C, Welch V,  Gater A, Amer K, Hohman R, Stein J,   Brown A., Russell N,  LeBlanc T June 4, 2021 ASCO 2021 Hematology

A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML)

View Presentation View Abstract Plain Language Summary
Poster Discussion
de Lima M, Kebriaei P,   Lanza  F, Cho C, Giralt S, Popradi G,   Hemmer M, Zhang X, Shah R,   Welch V, Vandendries E, Stelljes M, Marks D, Saber W June 4, 2021 ASCO 2021 Hematology

A Registry-based, Observational Safety Study of Inotuzumab Ozogamicin (InO) Treatment in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Who Proceeded to Hematopoietic Stem Cell Transplant (HSCT)

View Presentation View Abstract Plain Language Summary
Poster
Deininger M, Brummendorf T, Milojkovic D, Cervantes F, Huguet F, Viqueira A, Leip E, Purcell S, Cortes J June 4, 2021 ASCO 2021 Hematology

Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib 

View Presentation View Abstract Plain Language Summary
Poster
Gambacorti-Passerini C, Brummendorf TH, Kim D-W, Goh YT, Dyagil I, Pagnano K, Batai A, Turkina AG, Leip E, Purcell S, Leone J, Viqueira A, Cortes JE June 4, 2021 ASCO 2021 Hematology

Second-line bosutinib (BOS) for patients with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study

View Presentation View Abstract Plain Language Summary
Poster Discussion
Brummendorf T, Cortes J, Busque L, Gambacorti-Passerini C, Stenke L, Viqueira A, Leip E, Purcell S, Deininger M June 4, 2021 ASCO 2021 Hematology

The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia

View Presentation View Abstract Plain Language Summary
Oral Presentation
Bahlis N, Raje N, Costello C, Dholaria B, Solh M, Levy M, Tomasson M, Dube H, Liu F, Liao K, Basu C, Skoura A, Chan E, Trudel S, Jakubowiak A, Chu M, Gasparetto G, Dalovisio A, Sebag M, Lesokhin A June 8, 2021 ASCO 2021 Hematology

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). 

View Presentation View Abstract Plain Language Summary
Poster
Marks D, de Lima M, Kebriaei P, Lanza F, Cho C, Giralt S, Popradi G, Hemmer M, Zhang X, Shah R, Welch V, Vandendries E, Stelljes M, Saber W June 9, 2021 EHA 2021 Hematology

A Registry-based, Observational Safety Study of Inotuzumab Ozogamicin in Patients (Pts) with B-Cell Precursor Acute Lymphoblastic Leukemia Proceeding to Hematopoietic Stem Cell Transplant

View Presentation View Abstract Plain Language Summary
Oral Presentation
Costello CL, Raje NS, Bahlis NJ, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore M, Liao K, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM June 9, 2021 EHA 2021 Hematology

MagnetisMM-1: Phase 1 study of elranatamab (PF-06863135), a B-cell maturation antigen targeted CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma

View Presentation View Abstract Plain Language Summary
Poster
Deininger M, Brummendorf T, Milojkovic D, Cervantes F, Huguet F, Viqueira A, Leip E, Purcell S, Cortes J June 9, 2021 EHA 2021 Hematology

Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib

View Presentation View Abstract Plain Language Summary